Geron's Q4 Results: TD Cowen Trims PT to $3, Maintains Buy Rating

Geron Corporation (NASDAQ:GERN) is a commercial-stage biopharmaceutical company that develops therapeutic products for oncology. TD Cowen analyst Tara Bancroft reduced the firm's price target on Geron to $3 from $4 while keeping a Buy rating, ahead of Q4 2025 results. The firm's financial model was updated to reflect the company's Q3 2025 results, which showed a 15% sequential increase in ordering accounts and the initiation of its first shipment of RYTELO to Germany under an early access program. Geron's clinical pipeline remains on track, with a Phase 3 trial for relapsed/refractory myelofibrosis fully enrolled and an interim analysis expected in the second half of 2026.